JPMorgan analyst Robbie Marcus raised the firm’s price target on Edwards Lifesciences (EW) to $78 from $72 and keeps a Neutral rating on the shares following the Q3 report. The firm thinks it will take additional quarters for Edwards to convince investors that it found the bottom for the TAVR franchise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $68 from $73 at Baird
- Closing Bell Movers: Deckers up 12% after earnings beat
- Edwards Lifesciences reports Q3 adjusted EPS 67c, consensus 64c
- Edwards Lifesciences backs FY24 revenue growth view 8%-10%, consensus $1.44B
- Edwards Lifesciences sees Q4 EPS 53c-57c, consensus 62c